Utama › Karsinoma Nasofaring
Kajian klinikal Karsinoma Nasofaring sedang mengambil peserta di AS
13 kajian untuk Karsinoma Nasofaring sedang mengambil peserta di lokasi seluruh Amerika Syarikat.
Bandar dengan paling banyak kajian
- Atlanta, GA6 kajian
- Pittsburgh, PA3 kajian
- Houston, TX3 kajian
- Milwaukee, WI3 kajian
- Oklahoma City, OK3 kajian
- Cincinnati, OH3 kajian
- Charlotte, NC3 kajian
- Chicago, IL3 kajian
- Washington, DC3 kajian
- Los Angeles, CA3 kajian
- San Francisco, CA3 kajian
- Richmond, VA3 kajian
Mengikut negeri
- California6 kajian
- Georgia6 kajian
- Illinois3 kajian
- Maryland3 kajian
- Missouri3 kajian
- North Carolina3 kajian
- Ohio3 kajian
- Oklahoma3 kajian
- Pennsylvania3 kajian
- South Carolina3 kajian
- Texas4 kajian
- Virginia4 kajian
- Wisconsin3 kajian
Kajian yang dikemas kini baru-baru ini
Teks kajian rasmi (Bahasa Inggeris)
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
Mengambil pesertaFasa 1
Umur 18 hingga 120 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06479811Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06980038Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT06029270A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
Mengambil pesertaFasa 2
Sehingga umur 21 · Semua jantina · Dikemas kini 14 Sep 2026 · NCT06064097Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT06532279A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT07749586Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Jul 2026 · NCT06662058Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Jul 2026 · NCT01365169Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Jun 2026 · NCT06592599Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Jun 2026 · NCT06682442Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Apr 2026 · NCT03010150TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Mac 2026 · NCT06868433Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Feb 2026 · NCT06636734Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.